Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.

Abstract

In cases of ovarian carcinoma, primary cytoreductive surgery (CRS) is the standard treatment up to stage IIIB, but patient selection for neoadjuvant chemotherapy (NACT) in selected cases is controversial. A total of 200 patients withadvanced ovarian cancer were analyzed retrospectively, according tospecificselection criteria. Primary CRS was performed in 95 patients (47.5%) and interval CRS after 3-6 cycles of NACT was performedin 105 patients (52.5%). After median follow-up of 35months, 5-year overall survivalwas 53.7% in the upfront CRS group and 42.2%in theNACT group. Primary CRS is the standard in advanced stages of ovariancarcinoma, but in certain subset of patients, NACT is preferred. Identifying that group is challenging but feasible. Proper selection of patients iskey to successful outcomes.